-
Innovation Ranking
NewInnovation Ranking – Vifor Pharma Ltd
Vifor Pharma Management Ltd (CSL Vifor) formerly Galenica Ltd, focuses on discovery, development, and marketing of prescription medicines and non-prescription drugs. The company offers intravenous pharmaceuticals for iron deficiency, besides products for nephrology and cardio-renal therapies. It also provides pharmaceuticals for the treatment of respiratory tract infections, ear care, abdominal distension, chronic obstructive pulmonary disease, hemorrhoids, chronic venous insufficiency, diabetic retinopathy, lower urinary tract infections, menometrorrhagia, chronic kidney disease, and hyperkalemia. Vifor Pharma also discovers, develops, and markets polymeric medicines...
-
Company Insights
Innovation and Patenting activity of Vifor Pharma AG Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Vifor Pharma AG Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Company Insights
Innovation and Patenting activity of Vifor Pharma Management Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Vifor Pharma Management Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ferric Carboxymaltose in Restless Legs Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ferric Carboxymaltose in Restless Legs Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ferric Carboxymaltose in Restless Legs Syndrome Drug Details: Ferric carboxymaltose...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ferric Carboxymaltose in Chemotherapy Induced Anemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ferric Carboxymaltose in Chemotherapy Induced Anemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ferric Carboxymaltose in Chemotherapy Induced Anemia Drug Details: Ferric carboxymaltose...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Izeltabart Tapatansine in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Izeltabart Tapatansine in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Izeltabart Tapatansine in Triple-Negative Breast Cancer (TNBC) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ferric Carboxymaltose in Congestive Heart Failure (Heart Failure)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ferric Carboxymaltose in Congestive Heart Failure (Heart Failure) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ferric Carboxymaltose in Congestive Heart Failure (Heart Failure)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Famitinib in Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Famitinib in Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Famitinib in Squamous Cell Carcinoma Drug Details: Famitinib (SHR-1020) is under...
-
Product Insights
Hemochromatosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemochromatosis - Drugs In Development, 2023’, provides an overview of the Hemochromatosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemochromatosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NLG-207 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NLG-207 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NLG-207 in Transitional Cell Carcinoma (Urothelial Cell Carcinoma)...